Aehr Test Systems Shares Jump 5.3% Amid Valuation Concerns

Aehr Test Systems (AEHR) shares climbed 5.3% to close at $95.56 on September 9, 2026. The move contributed to a year-to-date increase of 373.3%, positioning the stock well within its 52-week range of $18.70 to $147.40. Despite this recent rebound, the shares have declined 7.3% over the past month, reflecting volatility in a stock that has seen substantial appreciation since the start of the year.

The price action occurs against a backdrop of mixed fundamental signals. While the company maintains a solid balance sheet, its current market price stands significantly higher than intrinsic value estimates. Aehr remains unprofitable, which complicates traditional earnings-based valuation and leads analysts to rely on sales multiples and composite scoring models to assess the stock's relative standing.

Valuation Metrics Indicate High Premium

According to data reviewed by GN stocks/shares-surge, the current trading price is substantially above the calculated intrinsic value. The estimated value stands at $13.46, implying a premium of 610% over this baseline. Because Aehr is not generating positive earnings, the Price-to-Earnings ratio is less applicable, with a trailing twelve-month multiple of 126.1x compared to a five-year median of 39.7x.

Investors are instead looking at the Price-to-Sales ratio, which has historically hovered around 4.7x for the company. The current market price trades well above this historical median, suggesting that the market is pricing in expectations that are not yet reflected in the company’s financial results. This divergence between market price and historical sales multiples highlights the speculative nature of the recent price gains.

Composite Score Reveals Mixed Fundamentals

A composite score of 64 out of 100 places Aehr above the average performer, but the breakdown reveals significant internal contradictions. The company scores well on financial strength and growth potential, both rated 7 out of 10, indicating a solid balance sheet and reasonable expansion prospects. However, the valuation sub-score is rated a mere 1 out of 10, underscoring the disconnect between the stock price and its perceived worth.

Profitability is another weak area, with a rating of 4 out of 10. This low score aligns with the company’s ongoing unprofitability and negative cash flow. The momentum sub-score of 6 out of 10 suggests that while the stock has recent upward pressure, the underlying financial performance does not fully support the current valuation levels.

Insider Activity Signals Caution

Insider trading data presents a bearish signal for the stock. Over the past 12 months, insiders sold shares worth $62.7 million without any corresponding buying activity. This one-way flow of shares from company executives to the market suggests a lack of confidence in the current price point or future short-term prospects from those closest to the business.

Professional investor activity is similarly divided. Six gurus currently hold positions in AEHR, but recent quarters have seen three increase their stakes while four have trimmed theirs. This mixed behavior indicates a lack of consensus among professional investors, with some taking profits while others remain invested. The combination of heavy insider selling and split guru activity suggests a cautious sentiment toward the stock's valuation.